Radiofrequency Ablation Versus Partial Nephrectomy in Patients with Solitary Clinical T1a Renal Cell Carcinoma: Comparable Oncologic Outcomes at a Minimum of 5 Years of Follow-Up

Olweny, Ephrem O.; Park, Samuel K.; Tan, York Kiat; Best, Sara L.; Trimmer, Clayton; Cadeddu, Jeffrey A.

doi:10.1016/j.eururo.2012.01.001

Cited by 190 publications

(97 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The efficacies of ablative therapies, including radiofrequency (RF) ablation (RFA) and cryoablation, have been reported previously: A number of authors have reported long-term results following RFA for RCC and demonstrated excellent oncological outcomes (14)(15)(16)(17)(18)(19)(20). In our institute, percutaneous RFA for renal cancer was initiated in 2005.…”

Section: Introductionmentioning

confidence: 99%

Clinical outcomes of percutaneous radiofrequency ablation for small renal cancer

et al. 2017

View full text Add to dashboard Cite

Abstract. Partial nephrectomy is the treatment of choice for small renal cell carcinoma (RCC) from the perspective of cancer management and renal function. However, when patients with RCC are of advanced age, exhibit severe comorbidities, including cardiovascular and pulmonary diseases, or have hereditary RCC, ablative therapies, including radiofrequency ablation (RFA) and cryoablation are useful treatment options. In the present study, the clinical outcomes of percutaneous RFA for treating small RCC were evaluated. Between December 2005 and March 2015, 40 patients (41 renal tumors in total) underwent RFA and a total of 50 sessions of RFA were performed. The average tumor size was 2.5 cm. A total of 18 tumors were exophytic and 23 were parenchymal. Of the 41 tumors, 85.4% were completely ablated by initial RFA and the rate of complete ablation following reablation for residual viable lesions was 95.1%. Local recurrence-free survival following complete ablation was 84.2% at 3 years. A patient with a 4.7 cm RCC tumor rapidly progressed following four RFA treatments until complete ablation was achieved. The metastasis-free survival rate following initial RFA was 95.7% at 3 years. The RCC-specific survival was 100% (mean follow-up, 38 months). Adverse events occurred in five sessions (10%); however, only 1 patient with arteriovenous fistula required intervention (transarterial embolization). The mean hospital stay following RFA was 3.2 days. The mean decrease in estimated glomerular filtration rate following RFA was 2.7%. The results of the present study indicate that percutaneous RFA was an effective treatment for small RCCs with respect to management of cancer, minimal invasiveness and minimal loss of renal function, particularly in patients for whom surgery would be a high risk and those at increased risk of deterioration of renal function.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical outcomes of percutaneous radiofrequency ablation for small renal cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The established ablative method for renal cell carcinomas (RCCs) is RFA, which shows comparable oncologic outcomes to partial nephrectomy with more preservation of nephron function (6)(7)(8). CA seems to offer the advantages of minimally invasive surgery with a significantly lower late complication rate than laparoscopic partial nephrectomy (2.2% vs. 16.3%, respectively) (9).…”

mentioning

confidence: 99%

Meta-analysis of cryoablation versus microwave ablation for small renal masses: is there a difference in outcome?

Martin¹,

Athreya²

2013

Diagn Interv Radiol

View full text Add to dashboard Cite

ORIGINAL ARTICLE PURPOSE We aimed to compare local and metastatic recurrence of small renal masses primarily treated by cryoablation or microwave ablation. MATERIALS AND METHODSThe MEDLINE, CINAHL, and PUBMED databases were searched to review the treatment of small renal masses with cryoablation or microwave ablation. Fifty-one studies met the inclusion criteria. RESULTSFifty-one studies representing 3950 kidney lesions were analyzed. No differences were detected in the mean patient age (P = 0.150) or duration of follow-up (P = 0.070). The mean tumor size was significantly larger in the microwave ablation group compared with the cryoablation group (P = 0.030). There was no difference between microwave ablation and cryoablation groups in terms of primary effectiveness (93.75% vs. 91.27%, respectively; P = 0.400), cancer-specific survival (98.27% vs. 96.8%, respectively; P = 0.470), local tumor progression (4.07% vs. 2.53%, respectively; P = 0.460), or progression to metastatic disease (0.8% vs. 0%, respectively; P = 0.120). Patient age was predictive of overall complications in the multivariate analysis (P = 0.020). Local tumor progression with cryoablation was predicted by the mean follow-up duration using univariate (P = 0.009) and multivariate regression (P = 0.003). Clear cell and angiomyolipoma were more frequent in the microwave ablation group (P < 0.0001 and P = 0.03328, respectively), and papillary, chromophobe, and oncocytoma were more frequent in the cryoablation group (P < 0.0001, P < 0.0001, and P = 0.0004, respectively). Open access was used more often in the microwave ablation group than in the cryoablation group (12.20% vs. 1.04%, respectively; P < 0.0001), and percutaneous access was used more frequently in the cryoablation group than in the microwave ablation group (88.64% vs. 37.20%, respectively; P = 0.0021). CONCLUSIONThere is no difference in local or metastatic recurrence between cryoablation-and microwave ablation-treated small renal masses.

show abstract

“…Bu çalışmanın yazarları, rekürrenssiz sağ kalım oranını %94 olarak rapor etmiş, RFA tedavisinin uzun dönem sonuçlarının ekstirpasyon tedavisi ile benzer olduğunu bildirmiştir. T1a evresindeki böbrek hücreli kanser olgularında RFA (n=37) ile laparoskopik parsiyel nefrektomi (n=37) yapılan hastaların 5 yıllık takip sonuçlarının karşılaştırıldığı yakın zamanda yayımlanmış bir çalışmada, RFA ve parsiyel nefrektomi grubunda sırası ile genel sağ kalım oranı %97.2 ve %100 (p=0.31), hastalıksız sağ kalım oranı %89.2 ve %89.2 (p=0.78), lokal rekürressiz sağ kalım oranı %91.7 ve %94.6 (p=0.96) ve metastassız sağ kalım oranı %97.2 ve %91.8 (p=0.35) olarak rapor edilmiştir (33). Bu çalışmanın yazarları, seçilmiş hasta grubunda RFA tedavisinin uzun dönem sonuçlarının parsi-yel nefrektomi ile karşılaştırılabilir olduğunu bildirmiştir.…”

Section: Onkolojik Etkinlikunclassified

Küçük Böbrek Kitlelerinin Minimal İnvaziv Tedavisinde Kriyoablasyon mu, Radyofrekans Ablasyon mu?

Tuncel¹,

Senel²,

Aslan³

2015

Endouroloji

View full text Add to dashboard Cite

Radiofrequency Ablation Versus Partial Nephrectomy in Patients with Solitary Clinical T1a Renal Cell Carcinoma: Comparable Oncologic Outcomes at a Minimum of 5 Years of Follow-Up

Cited by 190 publications

References 16 publications

Clinical outcomes of percutaneous radiofrequency ablation for small renal cancer

Clinical outcomes of percutaneous radiofrequency ablation for small renal cancer

Meta-analysis of cryoablation versus microwave ablation for small renal masses: is there a difference in outcome?

Küçük Böbrek Kitlelerinin Minimal İnvaziv Tedavisinde Kriyoablasyon mu, Radyofrekans Ablasyon mu?

Contact Info

Product

Resources

About